Beyond Age and Fitness: Personalized Treatment Selection with Zanubrutinib in Real-World Patients with Chronic Lymphocytic Leukemia — A Case Series, Scoping Review and Expert Survey from the Apulian Hematology Network (REP)

To report real-world experience with zanubrutinib, a highly selective second-generation covalent Bruton tyrosine kinase inhibitor (BTKi), in complex CLL patients managed within a regional hematology network; to map the published evidence on zanubrutinib relevant to these scenarios; and to capture how regional experts approach the same clinical questions.